RegulatoryApr 28, 2026, 04:33 PM
QNCX Regains Nasdaq Bid Price Compliance; MVLS Non-Compliance Remains
AI Summary
Quince Therapeutics, Inc. announced it has regained compliance with the Nasdaq minimum bid price requirement, with its common stock closing at or above $1.00 for 10 consecutive business days. However, the company has not yet regained compliance with Nasdaq's $50,000,000 market value of listed securities (MVLS) requirement. Quince Therapeutics has until September 14, 2026, to regain MVLS compliance, with no assurance of success.
Key Highlights
- Quince Therapeutics, Inc. regained compliance with Nasdaq's minimum bid price requirement.
- The company's common stock closing bid price was $1.00 or greater for 10 consecutive business days from April 13-24, 2026.
- Nasdaq considers the minimum bid price matter closed.
- The company remains non-compliant with the Nasdaq Global Select Market's $50,000,000 market value of listed securities (MVLS) requirement.
- The deadline to regain MVLS compliance is September 14, 2026.
Price Impact
More from QNCX
Management ChangeJul 31, 4:57 PM
Quince Therapeutics Announces Conditional CEO, CFO, COO Appointments
AcquisitionsJul 30, 6:08 AM
Quince Therapeutics Files Orphai Acquisition Financials & Business Update
Business UpdateJun 30, 8:02 AM
Quince Therapeutics Forms Scientific Advisory Board for LAM-001 Development